Lupin Receives FDA Clearance for Two Key Facilities Following Successful Regulatory Inspections
Key Insights
Lupin Limited received Establishment Inspection Reports (EIR) from the U.S. FDA (search) for both its global pharmacovigilance operations in Mumbai and its Inhalation Research Center in Florida.
The Mumbai facility's pharmacovigilance inspection focused on post-marketing adverse drug experience reporting practices and closed with four observations after comprehensive scrutiny.
The Florida inhalation research center, which develops respiratory products for asthma (search) and COPD treatment, received satisfactory VAI status following inspection for a generic Fostair application.
Lupin Limited announced it has received Establishment Inspection Reports (EIR) from the U.S. Food and Drug Administration for two critical facilities, marking successful closure of regulatory inspections for both its global pharmacovigilance operations and respiratory product development capabilities.
Pharmacovigilance Operations Clear FDA Review
The company's Drug Safety & Risk Management (DSRM) group based in Mumbai received EIR clearance following a Post-marketing Adverse Drug Experience (PADE) inspection conducted between January 14-18, 2019. The inspection included comprehensive scrutiny of practices and procedures for reporting adverse events of Lupin's marketed products worldwide, ultimately closing with four observations.
The pharmacovigilance inspection represents a critical regulatory milestone for Lupin's global drug safety monitoring capabilities, which oversee adverse event reporting for the company's extensive portfolio across more than 100 markets.
Respiratory Research Center Achieves Regulatory Milestone
Lupin's Inhalation Research Center in Coral Springs, Florida, received its EIR with satisfactory VAI status following an inspection conducted February 19-26, 2020. The U.S. FDA (search) conducted this inspection on behalf of the U.K. MHRA (search) for Lupin's generic Fostair application to the U.K. regulatory authority.
The Florida facility, inaugurated in August 2015, focuses specifically on research and development of respiratory products for treating asthma (search), chronic obstructive pulmonary diseases (search), and other respiratory ailments.
Strategic Importance During Pandemic
CEO Vinita Gupta emphasized the timing significance of the regulatory clearance, stating, "The Inhalation Research Center at Florida was established to develop quality respiratory products to benefit patients across the U.S. and other advanced markets. The receipt of the EIR with satisfactory VAI status validates our commitment towards ensuring the highest levels of quality and CGMP compliance at all our sites."
Gupta highlighted the critical nature of respiratory product development during the COVID-19 (search) pandemic, noting, "We are grateful for the U.S. FDA (search)'s confidence in our team during this critical juncture in the fight against COVID-19, when it has become imperative that we focus on bringing high quality respiratory products to market."
Company Profile and Market Position
Lupin operates as an innovation-led transnational pharmaceutical company headquartered in Mumbai, developing and commercializing branded and generic formulations, biotechnology products, and APIs across global markets. The company holds leadership positions in cardiovascular, anti-diabetic, and respiratory segments while maintaining significant presence in anti-infective, gastro-intestinal, central nervous system, and women's health areas.
According to company data, Lupin ranks as the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The company invests 9.6% of its revenues in research and development activities across fifteen manufacturing sites and seven research centers, employing more than 20,000 professionals globally.